法国Servier公司为2.5B购买第1天生物药,以扩大罕见的癌症治疗,包括儿科药物。 French firm Servier buys Day One Biopharma for $2.5B to expand rare cancer treatments, including pediatric drugs.

法国制药公司Servier同意以25亿美元的现金购买第1天生物药品,每股21.50美元,即68%的溢价,以扩大其罕见的肿瘤管道,特别是儿科癌症管道。 French pharmaceutical company Servier has agreed to acquire Day One Biopharmaceuticals for $2.5 billion in cash, paying $21.50 per share, a 68% premium, to expand its rare oncology pipeline, particularly in pediatric cancers. 该交易预计于2026年第二季度完成，包括Day One获得FDA批准的用于儿童低级别胶质瘤的药物Ojemda及其抗体药物偶联物的管线，其中包括针对实体肿瘤的一期临床项目。 The deal, expected to close in the second quarter of 2026, includes Day One’s FDA-approved drug Ojemda for pediatric low-grade glioma and its pipeline of antibody drug conjugates, including a Phase 1 program for solid tumors. 服务员的目标是利用其全球影响力,加快患者的就诊速度,推进其肿瘤增长战略,到2030年实现每年40亿欧元的销售目标。 Servier aims to leverage its global reach to accelerate patient access and advance its oncology growth strategy, which targets €4 billion in annual sales by 2030. 公司董事会批准了这笔交易, 股价在宣布之后升了65.7%. Day One’s board has approved the transaction, and its shares surged 65.7% following the announcement.